Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. - Wikidata - wikimedia - TriplyDB

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

http://www.wikidata.org/entity/Q46642975

about

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies Cell of origin fails to predict survival in patients with diffuse large B-cell lymphoma treated with autologous hematopoietic stem cell transplantation.Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3 Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy.Evolution of R-CHOP therapy for older patients with diffuse large B-cell lymphoma.Management of relapsed-refractory diffuse large B cell lymphoma.Transplantation for non-Hodgkin lymphoma.Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma.Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.Complexity made simple in diffuse large B-cell lymphoma.Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell Impact of germinal center and non-germinal center phenotypes on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma.pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.Prognostic value of chromosomal translocations in small-bowel diffuse large B-cell lymphoma.A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line che High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma.Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma

P2860

Q28256567-F6B93158-8725-4D9C-903D-8CA1D9530BCB Q33700531-A92118A0-CC96-4810-88CF-F7FC5E6B8B10 Q34325329-09772001-9AD3-4756-B7B0-638E1ED0FE62 Q34390837-A5B7D880-111E-4836-BA1D-31538AE2EAA0 Q35915899-9A9639A7-46FA-44E5-AE0A-A27FBDA7E332 Q36971217-83E94431-B446-4221-9BAF-9D698A25A077 Q37045955-E4D24A29-E657-4732-97A9-6DC126EEDC06 Q37083601-D88FCFAD-2B4D-4455-806D-66081362F14C Q37109671-981FD2AE-01B0-49E2-A7C2-705228451505 Q37293519-9B59678D-FEB9-4FA5-9C03-D0F05613187B Q37300030-549CBCA5-AFD3-4D30-ABC2-6338C26C5B38 Q37654010-FAE3E471-1FDB-42EE-A10B-8BB7BD9A1191 Q37810079-7EAA5285-0B32-44DE-B508-2B1A6617C9AB Q37944927-874E94BC-069B-4006-AAB3-1B6D344480F4 Q38782069-335BAC7A-95B6-420A-8D9D-64AD1B642B93 Q40144297-90A4C726-BD6A-4696-8C24-8221438BE582 Q42544455-DFAF8317-0401-46DE-ACA7-365E5D3A6D13 Q43254046-C1387DD5-291D-4CC3-AAA7-87EF3A0F3ECF Q45382904-8E6B2FA3-6561-49C6-BDFF-C45553DADC9D Q45948514-22541254-DE6C-42D8-9A67-4F1FEB5590B9 Q46008262-F39397AB-5ECC-410A-9CCD-07426F62C185 Q49074527-D395D6B0-B79D-40CE-B3DD-E93179C59025 Q50247640-06FC68E1-49B1-4FAC-A27A-9570D63E1138 Q51815607-351A99A9-34ED-42F7-80DE-7812069F6067 Q53089847-80E18B83-D9E3-4C63-A752-334269BEE8B3 Q53137051-B228468B-BA8A-46EE-B823-BC3EF547D7D7 Q56882990-05ECAFD5-96C0-4B29-A343-2023FEB0B7FC

P2860

Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL.

http://www.wikidata.org/entity/Q46642975

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@en

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@nl

type

label

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@en

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@nl

prefLabel

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@en

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@nl

P1433

Q46642975-943D5C84-B438-41B6-BAE4-2F457C26327E

P1476

Q46642975-6740335C-1DBD-4242-9956-AB6C5CE042C9

P2093

Q46642975-1E27E832-9AAC-48E4-8EC3-D00096E1E927

Q46642975-6B142CD3-4363-4F11-816C-1057802E7E21

Q46642975-8359C499-6112-4808-AAC7-51DBA0D456AD

Q46642975-8908C0E9-75C8-4FE9-AF18-B648CC0E5B03

Q46642975-89EF40A2-E431-4428-B6E4-4112ABA6E557

Q46642975-94B21F45-19D7-499E-B567-A7F1913B0DBD

Q46642975-B3CF3DAE-076F-46FB-835D-AABB67F39BC2

Q46642975-CA9F15A3-138E-4DF9-BA71-0475E0BAF0DE

P304

Q46642975-A83E21A1-9050-42F1-A150-E9FF3C8A6DFB

P31

Q46642975-3815060C-B446-4A60-B4F9-DA8F1E57374B

P356

Q46642975-A5EB0A62-89CB-4711-B47A-6BF66BFB4593

P407

Q46642975-FFE03BC2-E7DA-4B7B-B5F6-FDD8E51225F8

P433

Q46642975-3A1E1173-08FA-47F1-B8A7-25E881478DB8

P478

Q46642975-F4AC0955-2947-4F5F-8D8F-41B58E3EF57E

P50

Q46642975-4FAA9397-52A7-4DC1-ABD7-2333178A22B2

Q46642975-B341FBB9-D8A2-4852-8784-0F70096B8233

P577

Q46642975-5BF9D139-1BB9-469C-8718-773AE110C6EA

P5875

Q46642975-C6007F27-0ED6-40D6-AC39-00EFA5B53C4F

P698

Q46642975-956CE9EF-FD80-496D-986A-93C8373F139C

P921

Q46642975-39F09F5F-D7CA-4E28-8005-AC10F0F5047E

P356

BLOOD-2005-04-1603

P1433

P1476

Cell of origin, germinal cente ...... relapsed and refractory DLBCL.

@en

P2093

Adam Olshen

http://www.w3.org/2001/XMLSchema#string

Craig H Moskowitz

http://www.w3.org/2001/XMLSchema#string

Jane Houldsworth

http://www.w3.org/2001/XMLSchema#string

Julie Teruya-Feldstein

http://www.w3.org/2001/XMLSchema#string

Raju Chaganti

http://www.w3.org/2001/XMLSchema#string

Simone Lessac-Chenen

http://www.w3.org/2001/XMLSchema#string

Stephen Nimer

http://www.w3.org/2001/XMLSchema#string

Tarun Kewalramani

http://www.w3.org/2001/XMLSchema#string

P304

3383-3385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-04-1603

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Andrew D Zelenetz

P577

2005-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7669804

http://www.w3.org/2001/XMLSchema#string

P698

16091454

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry